GlobeNewswire by notified

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance


Paris (France), 26 October 2023

Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today presents its sales performance for the year to date and the third quarter of 2023.

% changeQ3
% change
Oncology 1,744.1 1,767.2 -1.3% 0.8% 574.5 603.1 -4.7% 0.8%
Neuroscience 489.0 407.7 19.9% 24.5% 164.8 160.7 2.5% 13.7%
Rare Disease 76.0 33.6 n/a n/a 33.2 11.0 n/a n/a
Total Sales 2,309.12,208.54.6%7.1%772.4774.8-0.3%6.5%

Sales and pipeline highlights

  1. Total-sales growth in the year to date of 7.1% at CER1, or 4.6% as reported, driven by the performance of the growth platforms2, up by 16.1%1, with Dysport® (abobotulinumtoxinA) up by 24.7%1 and Cabometyx® (cabozantinib) up by 24.4%1, respectively. The performance included contributions from new medicines Bylvay® (odevixibat), Tazverik® (tazemetostat) and Sohonos® (palovarotene)

  1. Further pipeline progress, including the regulatory approval and launch in the U.S. of Sohonos® in Rare Disease and initial results from the CONTACT-02 Phase III trial of Cabometyx® plus atezolizumab in Oncology

David Loew, Chief Executive Officer, commented:
“Ipsen’s strategic success has been reflected in further sales and pipeline progress so far this year. Our portfolio has performed well across the three therapy areas, driven by strengthened commercial execution and the results of our external-innovation strategy. Based on the solid sales momentum, today we are confirming our guidance for the full year.

Further good news from the pipeline, including the regulatory approval of Sohonos in the U.S., continue to provide additional options for patients with real unmet medical needs. In the final quarter of the year, we look forward to regulatory steps for elafibranor in primary biliary cholangitis, as well as sharing further details on sustainable growth opportunities across our portfolio and pipeline at our forthcoming capital-markets day.”

Full-year 2023 guidance
Ipsen has confirmed its financial guidance for FY 2023:

  • Total-sales growth greater than 6.0%, at constant exchange rates. Based on the average level of exchange rates in September 2023, an adverse impact on total sales of around 3.5% from currencies is expected

  • Core operating margin greater than 30% of total sales

Pipeline development

In August 2023, it was announced that the U.S. Food and Drug Administration (FDA) had approved Sohonos, the first and only treatment for people with fibrodysplasia ossificans progressiva.

It was also announced that the global CONTACT-02 pivotal Phase III trial of Cabometyx plus atezolizumab in metastatic castration-resistant prostate cancer met one of two primary endpoints, demonstrating a statistically significant improvement in progression-free survival at the primary analysis.

In October 2023, the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products confirmed its negative opinion recommending not to maintain the orphan designation for Bylvay in Alagille syndrome (ALGS). This was despite a positive opinion from the Committee for Medicinal Products for Human Use in July 2023. To maintain Bylvay’s orphan designation in the approved treatment of progressive familial intrahepatic cholestasis, Ipsen is planning to resubmit to the EMA under a new brand name for the treatment of ALGS by the end of 2023.

Galderma partnership

In September 2023, the Arbitral Tribunal of the International Chamber of Commerce issued a final decision following a difference of opinion on the regulatory-submission strategy for the liquid botulinum toxin type A, QM1114. In October 2023, Ipsen announced that its partner, Galderma, had received a Complete Response Letter from the U.S. FDA related to its Biologics License Application for QM1114.

A second arbitration proceeding, related to the territorial scope of the Dysport/Azzalure® aesthetics’ partnership, is anticipated to conclude next year.

AASLD call
To accompany the presentation of the ELATIVE Phase III trial results at the American Association for the Study of Liver Diseases (AASLD) 2023 Annual World Congress, Ipsen plans to host a conference call for analysts and investors on 14 November 2023, at 4.30pm CET. Participants can access the call and its details by registering here; webcast details can be found here. A recording will be available on

Capital-markets day
The Company is planning to host a capital-markets event, starting at 12.30pm GMT on 7 December 2023 in London. The event will be webcast live and details will be available on in due course. In-person attendance will be by invitation only.

Ipsen intends to publish its full-year and fourth-quarter results on 8 February 2024.

Conference call: YTD 2023
A conference call and webcast for investors and analysts will begin today at 2pm CET. Participants can access the call and its details by registering here; webcast details can be found here. A recording will be available on


All financial figures are in € millions (€m). The performance shown in this announcement covers the nine-month period to 30 September 2023 (YTD 2023) and the three-month period to 30 September 2023 (Q3 2023), compared to nine-month period to 30 September 2022 (YTD 2022) and the three-month period to 30 September 2022 (Q3 2022), respectively, unless stated otherwise. Commentary is based on the performance in YTD 2023, unless stated otherwise.

Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With total sales of €3.0bn in FY 2022, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,300 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit


Craig Marks
Vice President, Investor Relations
+44 (0)7584 349 193
Nicolas Bogler
Senior Investor Relations Manager
+33 6 52 19 98 92

Amy Wolf
Vice President and Head of Corporate Brand Strategy
and Communications
+41 79 576 07 23

Ioana Piscociu
Senior Manager, Global Media Relations
+33 6 69 09 12 96

Forward-looking statements

The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines, which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s 2022 Universal Registration Document, available on

1 At constant exchange rates (CER), which excludes any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period.
2 Dysport, Decapeptyl® (triptorelin), Cabometyx and Onivyde® (irinotecan).


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Transactions in connection with share buy-back program11.12.2023 10:43:02 CET | Press release

Announcement A.P. Møller - Mærsk A/S – Transactions in connection with share buy-back program On 5 May 2021, A.P. Møller - Mærsk A/S (the “Company”) announced a share buy-back program of up to DKK 32bn (around USD 5bn) to be executed over a period of two years. On 2 November 2021, the Company decided to extend the current share buy-back program by additionally DKK 32 billion (around USD 5 billion) during 2024 and 2025 bringing the total program up to DKK 64 billion (around USD 10 billion). On 12 August 2022 the Company announced an increase of the share buy-back program up to DKK 84 billion (around USD 12 billion). As announced on 3 November 2023, during the fifth phase of the program running from 6 November 2023 up to 1 May 2024, the Company will buy back A and B shares for an amount of up to DKK 11bn. The fifth phase of the share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commissi

Transaktioner i henhold til aktietilbagekøbsprogram11.12.2023 10:43:02 CET | pressemeddelelse

SELSKABSMEDDELELSE A.P. Møller - Mærsk A/S – Transaktioner i henhold til aktietilbagekøbsprogram Den 5. maj 2021 annoncerede A.P. Møller - Mærsk A/S (“Selskabet”) et aktietilbagekøbsprogram til en værdi af op til DKK 32 mia. (ca. USD 5 mia.), der vil blive opkøbt over en periode på op til to år. Den 2. november 2021 besluttede Selskabet at forøge det nuværende aktietilbagekøbsprogram med yderligere DKK 32 mia. (ca. USD 5 mia.) i løbet af 2024 og 2025, hvilket bringer det samlede program op til i alt DKK 64 mia. (ca. USD 10 mia.). Den 12. august 2022 offentliggjorde Selskabet en forøgelse af aktietilbagekøbsprogrammet op til DKK 84 mia. (ca. USD 6 mia.). Som annonceret den 6. november 2023, vil Selskabet i femte fase af programmet, der løber fra 3. november 2023 til 1. maj 2024, købe egne A-aktier og B-aktier for et beløb op til DKK 11 mia. Femte fase af tilbagekøbsprogrammet gennemføres i overensstemmelse med EU Kommissionens forordning nr. 596/2014 af 16. april 2014 (MAR) og EU Kommis

Aktietilbagekøb i Sydbank – transaktioner i uge 4911.12.2023 10:12:24 CET | pressemeddelelse

Selskabsmeddelelse nr. 43/2023 Peberlyk 4 DK-6200 Aabenraa Telefon +45 74 37 37 37 Telefax +45 74 37 35 36 Sydbank A/S CVR-nr. DK 12626509, Aabenraa 11. december 2023 Aktietilbagekøb i Sydbank – transaktioner i uge 49 Sydbank offentliggjorde den 6. juli 2023 et aktietilbagekøbsprogram på 600 mio. kr. Aktietilbagekøbsprogrammet startede den 10. juli 2023 og vil være afsluttet senest den 31. januar 2024. Aktietilbagekøbsprogrammet sker med henblik på nedsættelse af aktiekapitalen i Sydbank og gennemføres efter bestemmelserne i Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. april 2014 og EU Kommissionens delegerede forordning (EU) 2016/1052 af 8. marts 2016, samlet kaldet Safe Habour-reglerne. Under aktietilbagekøbsprogrammet er gennemført følgende transaktioner: Antal aktierGennemsnitlig købskursTransaktions-værdi (kr.)Akkumuleret seneste meddelelse 1.678.800 532.188.278,0004. december 2023 05. december 2023 06. december 2023 07. december 2023 08. december 2